{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:25:24Z","timestamp":1791217524212,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.addr.2007.06.011","type":"journal-article","created":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T11:15:04Z","timestamp":1187176504000},"page":"59-68","source":"Crossref","is-referenced-by-count":261,"title":["PEG-uricase in the management of treatment-resistant gout and hyperuricemia"],"prefix":"10.1016","volume":"60","author":[{"given":"Merry R.","family":"Sherman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.P.","family":"Saifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Perez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2007.06.011_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11926-996-0029-z","article-title":"New developments in clinically relevant mechanisms and treatment of hyperuricemia","volume":"8","author":"Lee","year":"2006","journal-title":"Curr. Rheumatol. Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2007.06.011_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1906","article-title":"A concise history of gout and hyperuricemia and their treatment","volume":"8","author":"Nuki","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2007.06.011_bib3","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0149-2918(03)80158-3","article-title":"A literature review of the epidemiology and treatment of acute gout","volume":"25","author":"Kim","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2007.06.011_bib4","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10\u00a0years among older adults in a managed care population","volume":"31","author":"Wallace","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2007.06.011_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0272-6386(99)70295-7","article-title":"Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease","volume":"33","author":"Johnson","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.addr.2007.06.011_bib6","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2007.06.011_bib7","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1681\/ASN.2005010063","article-title":"Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link?","volume":"16","author":"Johnson","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2007.06.011_bib8","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/art.22014","article-title":"Gout and the risk of acute myocardial infarction","volume":"54","author":"Krishnan","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2007.06.011_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/01.HYP.0000254480.64564.b6","article-title":"Hyperuricemia and incidence of hypertension among men without metabolic syndrome","volume":"49","author":"Krishnan","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.addr.2007.06.011_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J. Mol. Evol."},{"key":"10.1016\/j.addr.2007.06.011_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1445-5994.2007.01315.x","article-title":"Emerging therapies in the long-term management of hyperuricaemia and gout","volume":"37","author":"Stamp","year":"2007","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.addr.2007.06.011_bib12","first-page":"54","article-title":"Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches","volume":"3","author":"Del Toro","year":"2005","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.addr.2007.06.011_bib13","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.2174\/138161205774913291","article-title":"Rasburicase: a new approach for preventing and\/or treating tumor lysis syndrome","volume":"11","author":"Bessmertny","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2007.06.011_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","article-title":"Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial","volume":"19","author":"Jeha","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2007.06.011_bib15","first-page":"69","article-title":"Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome","volume":"147","author":"Jeha","year":"2005","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.addr.2007.06.011_bib16","first-page":"392","article-title":"Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases","volume":"62","author":"Rozenberg","year":"1995","journal-title":"Rev. Rhum. Engl. Ed."},{"key":"10.1016\/j.addr.2007.06.011_bib17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1681\/ASN.V115974","article-title":"Renal transplant-associated hyperuricemia and gout","volume":"11","author":"Clive","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2007.06.011_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/ndt\/18.3.603","article-title":"Long-term efficacy of hyperuricaemia treatment in renal transplant patients","volume":"18","author":"Perez-Ruiz","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.addr.2007.06.011_bib19","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/art.20438","article-title":"Gout: on the brink of novel therapeutic options for an ancient disease","volume":"50","author":"Bieber","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2007.06.011_bib20","first-page":"126","article-title":"Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout","volume":"76","author":"Rundles","year":"1963","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"10.1016\/j.addr.2007.06.011_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0006-2952(66)90163-8","article-title":"Metabolic studies of allopurinol, an inhibitor of xanthine oxidase","volume":"15","author":"Elion","year":"1966","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2007.06.011_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am. J. Med."},{"issue":"8374","key":"10.1016\/j.addr.2007.06.011_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(84)91807-5","article-title":"Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol","volume":"1","author":"Pennell","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2007.06.011_bib24","first-page":"229","article-title":"Death following allopurinol hypersensitivity syndrome","volume":"107","author":"Hanger","year":"1994","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.addr.2007.06.011_bib25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bmj.331.7517.623","article-title":"Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia","volume":"331","author":"Guti\u00e9rrez-Mac\u00edas","year":"2005","journal-title":"Br. Med. J."},{"key":"10.1016\/j.addr.2007.06.011_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.addr.2007.06.011_bib27","series-title":"Abstract FRI0484, EULAR 2006 (European League against Rheumatism)","article-title":"The long-term clinical benefits of febuxostat vs allopurinol in subjects with gout: interim analysis of the EXCEL trial, an ongoing phase 3, open-label extension study","author":"Becker","year":"2006"},{"key":"10.1016\/j.addr.2007.06.011_bib28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2007.06.011_bib29","first-page":"190","article-title":"The lowering of blood uric acid by uricase injections","volume":"68","author":"Oppenheimer","year":"1941","journal-title":"Bull. Johns Hopkins Hosp."},{"key":"10.1016\/j.addr.2007.06.011_bib30","first-page":"40","article-title":"Further observations on the lowering of blood uric acid by uricase injections","volume":"73","author":"Oppenheimer","year":"1943","journal-title":"Bull. Johns Hopkins Hosp."},{"key":"10.1016\/j.addr.2007.06.011_bib31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1126\/science.125.3254.937","article-title":"Uricolytic activity of purified uricase in two human beings","volume":"125","author":"London","year":"1957","journal-title":"Science"},{"key":"10.1016\/j.addr.2007.06.011_bib32","unstructured":"F.F. Davis, T. Van Es, N.C. Palczuk, Non-immunogenic polypeptides (1979) US Patent 4,179,337, Enzon, Inc."},{"key":"10.1016\/j.addr.2007.06.011_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000458668","article-title":"Modification of yeast uricase with polyethylene glycol: disappearance of binding ability towards anti-uricase serum","volume":"24","author":"Nishimura","year":"1979","journal-title":"Enzyme"},{"key":"10.1016\/j.addr.2007.06.011_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000459146","article-title":"Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzyme activity","volume":"26","author":"Nishimura","year":"1981","journal-title":"Enzyme"},{"key":"10.1016\/j.addr.2007.06.011_bib35","first-page":"352","article-title":"Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase","volume":"219","author":"Abuchowski","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2007.06.011_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0005-2744(81)90173-X","article-title":"Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol)","volume":"660","author":"Chen","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2007.06.011_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.2042-7158.1984.tb04396.x","article-title":"Hypouricaemic effect after oral administration in chickens of polyethylene glycol-modified uricase entrapped in liposomes","volume":"36","author":"Nishida","year":"1984","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2007.06.011_bib38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/bc000119x","article-title":"Immunological properties of uricase conjugated to neutral soluble polymers","volume":"12","author":"Caliceti","year":"2001","journal-title":"Bioconjug. Chem."},{"issue":"8241","key":"10.1016\/j.addr.2007.06.011_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(81)90528-6","article-title":"Hypouricaemic effect of polyethylene glycol modified urate oxidase","volume":"2","author":"Davis","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2007.06.011_bib40","unstructured":"L.D. Williams, M.S. Hershfield, S.J. Kelly, M.G.P. Saifer, M.R. Sherman, PEG-urate oxidase conjugates and use thereof, (2003) US Patent 6,576,235 B1, Mountain View Pharmaceuticals, Inc. and Duke University."},{"key":"10.1016\/j.addr.2007.06.011_bib41","unstructured":"M.R. Sherman, MG.P. Saifer, L.D. Williams, M.S. Hershfield, S.J. Kelly, Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates, (2004) US Patent 6,783,965 B1, Mountain View Pharmaceuticals, Inc. and Duke University."},{"key":"10.1016\/j.addr.2007.06.011_bib42","unstructured":"M.S. Hershfield, S.J. Kelly, Urate oxidase, (2006) US Patent 7,056,713 B1, Duke University."},{"key":"10.1016\/j.addr.2007.06.011_bib43","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1681\/ASN.V1251001","article-title":"Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase","volume":"12","author":"Kelly","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2007.06.011_bib44","first-page":"629","article-title":"Immobilization of enzymes and affinity ligands onto agarose via stable and uncharged carbamate linkages","volume":"4","author":"Wilchek","year":"1982","journal-title":"Biochem. Int."},{"key":"10.1016\/j.addr.2007.06.011_bib45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0076-6879(87)35066-9","article-title":"Immobilization of proteins and ligands using chlorocarbonates","volume":"135","author":"Miron","year":"1987","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2007.06.011_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3164\/jcbn.21.101","article-title":"A simple and efficient method for preparation of monomethoxypolyethylene glycol activated with p-nitrophenylchloroformate and its application to modification of l-asparaginase","volume":"21","author":"Kito","year":"1996","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10.1016\/j.addr.2007.06.011_bib47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF02798546","article-title":"Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase","volume":"11","author":"Veronese","year":"1985","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.addr.2007.06.011_bib48","first-page":"576","article-title":"Improved conjugation of cytokines using high molecular weight poly(ethylene glycol): PEG-GM-CSF as a prototype","volume":"38","author":"Saifer","year":"1997","journal-title":"Polym. Preprints"},{"key":"10.1016\/j.addr.2007.06.011_bib49","series-title":"Poly(ethylene glycol) Chemistry and Biological Applications. ACS Symposium Series 680","first-page":"155","article-title":"Conjugation of high molecular weight poly(ethylene glycol) to cytokines: granulocyte-macrophage colony-stimulating factors as model substrates","author":"Sherman","year":"1997"},{"key":"10.1016\/j.addr.2007.06.011_bib50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0192-0561(85)90158-4","article-title":"Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase","volume":"7","author":"Tsuji","year":"1985","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.addr.2007.06.011_bib51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0014-827X(00)00031-8","article-title":"Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine)","volume":"55","author":"Schiavon","year":"2000","journal-title":"Farmaco"},{"key":"10.1016\/j.addr.2007.06.011_bib52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0021-9673(91)85014-7","article-title":"On-line characterization of polyethylene glycol-modified proteins","volume":"588","author":"Kunitani","year":"1991","journal-title":"J. Chromatogr."},{"issue":"Suppl. 9","key":"10.1016\/j.addr.2007.06.011_bib53","first-page":"S105","article-title":"Resolution of tophi with intravenous PEG-uricase in refractory gout","volume":"50","author":"Baraf","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2007.06.011_bib54","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1073\/pnas.91.2.742","article-title":"Hyperuricemia and urate nephropathy in urate oxidase-deficient mice","volume":"91","author":"Wu","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2007.06.011_bib55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/01926230490451707","article-title":"Applications of magnetic resonance imaging","volume":"32","author":"Maronpot","year":"2004","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.addr.2007.06.011_bib56","unstructured":"A.L. Martinez, M.R. Sherman, M.G.P. Saifer, L.D. Williams, Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof, (2004) PCT Patent Publication WO 2004\/030617 A2, Mountain View Pharmaceuticals, Inc."},{"key":"10.1016\/j.addr.2007.06.011_bib57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0968-0004(00)89080-5","article-title":"RASMOL: biomolecular graphics for all","volume":"20","author":"Sayle","year":"1995","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.addr.2007.06.011_bib58","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nsb1197-947","article-title":"Crystal structure of the protein drug urate oxidase-inhibitor complex at 2.05\u00a0\u00c5 resolution","volume":"4","author":"Colloc\u2019h","year":"1997","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.addr.2007.06.011_bib59","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/bc990076o","article-title":"Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds","volume":"10","author":"Lee","year":"1999","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2007.06.011_bib60","unstructured":"J. Hartman, S. Mendelovitz, A variant form of urate oxidase and use thereof, (2006) PCT Patent Publication WO 2006\/110761 A2, Savient Pharmaceuticals, Inc."},{"key":"10.1016\/j.addr.2007.06.011_bib61","unstructured":"J. Hartman, S. Mendelovitz, Variant forms of urate oxidase and use thereof, (2006) PCT Patent Publication WO 2006\/110819 A2, Savient Pharmaceuticals, Inc."},{"key":"10.1016\/j.addr.2007.06.011_bib62","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2007.06.011_bib63","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2007.06.011_bib64","series-title":"Abstract 807, American College of Rheumatology Annual Scientific Meeting. San Antonio, TX","first-page":"16","article-title":"Phase I study of PEGylated-uricase (Puricase\u00ae) in subjects with gout","author":"Sundy","year":"2004"},{"key":"10.1016\/j.addr.2007.06.011_bib65","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2007.06.011_bib66","series-title":"Abstract 1836, American College of Rheumatology Annual Scientific Meeting, San Diego, CA","first-page":"12","article-title":"A Phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and refractory gout","author":"Sundy","year":"2005"},{"key":"10.1016\/j.addr.2007.06.011_bib67","series-title":"Abstract THU0516, EULAR 2006 (European League against Rheumatism)","article-title":"A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and treatment-failure gout","author":"Sundy","year":"2006"},{"key":"10.1016\/j.addr.2007.06.011_bib68","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11926-007-0041-y","article-title":"Uricase and other novel agents for the management of patients with treatment-failure gout","volume":"9","author":"Sundy","year":"2007","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.addr.2007.06.011_bib69","series-title":"Abstract THU0465, EULAR 2006 (European League against Rheumatism)","article-title":"Resolution of tophi with intravenous PEG-uricase in treatment-failure gout","author":"Baraf","year":"2006"},{"key":"10.1016\/j.addr.2007.06.011_bib70","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0021-9258(19)81419-9","article-title":"Studies on uricase. I. Preparation, purification, and properties of a cuproprotein","volume":"216","author":"Mahler","year":"1955","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2007.06.011_bib71","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-109-2-114","article-title":"Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma","volume":"109","author":"Chua","year":"1988","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.addr.2007.06.011_bib72","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10067-005-0043-y","article-title":"Rasburicase treatment in severe tophaceous gout: a novel therapeutic option","volume":"25","author":"Moolenburgh","year":"2006","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.addr.2007.06.011_bib73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00128071-200405030-00003","article-title":"Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view","volume":"5","author":"Ruetter","year":"2004","journal-title":"Am. J. Dermatol."},{"key":"10.1016\/j.addr.2007.06.011_bib74","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma \u2014 a randomized Phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2007.06.011_bib75","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","article-title":"Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study","volume":"55","author":"Perez-Ruiz","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2007.06.011_bib76","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2007.06.011_bib77","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11926-004-0070-8","article-title":"The role of hypertension in cyclosporine-induced hyperuricemia","volume":"6","author":"Bieber","year":"2004","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.addr.2007.06.011_bib78","series-title":"Abstract THU0353, Annual European Congress of Rheumatology, Barcelona, Spain","first-page":"13","article-title":"Febuxostat versus allopurinol in the treatment of gout in subjects 65\u00a0years of age or older","author":"Schumacher","year":"2007"},{"key":"10.1016\/j.addr.2007.06.011_bib79","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/088391159701200303","article-title":"Branched and linear poly(ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates","volume":"12","author":"Veronese","year":"1997","journal-title":"J. Bioact. Compat. Polym."},{"key":"10.1016\/j.addr.2007.06.011_bib80","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/sj.leu.2400850","article-title":"Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies","volume":"11","author":"Pui","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2007.06.011_bib81","series-title":"Abstract 287, American College of Rheumatology Annual Scientific Meeting, New Orleans, LA","first-page":"25","article-title":"Phase I study of uricase formulated with polyethylene glycol (Uricase-PEG 20)","author":"Bomalaski","year":"2002"},{"key":"10.1016\/j.addr.2007.06.011_bib82","first-page":"1942","article-title":"Uricase formulated with polyethylene glycol (Uricase-PEG 20): biochemical rationale and preclinical studies","volume":"29","author":"Bomalaski","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2007.06.011_bib83","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11926-004-0075-3","article-title":"Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase","volume":"6","author":"Bomalaski","year":"2004","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.addr.2007.06.011_bib84","unstructured":"C.M. Ensor, M.A. Clark, F.W. Holtsberg, PEG-modified uricase, (2005) US Patent 6,913,915 B2, Phoenix Pharmacologics, Inc."},{"key":"10.1016\/j.addr.2007.06.011_bib85","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1345\/aph.1G272","article-title":"Hemolysis and methemoglobinemia secondary to rasburicase administration","volume":"39","author":"Browning","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.addr.2007.06.011_bib86","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1592\/phco.27.1.111","article-title":"Clarifying the role of rasburicase in tumor lysis syndrome","volume":"27","author":"Sood","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.addr.2007.06.011_bib87","unstructured":"Sanofi-Synthelabo, Inc., Elitek (rasburicase) product monograph, http:\/\/products.sanofi-aventis.us\/elitek\/elitek.html."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X0700138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X0700138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T19:50:52Z","timestamp":1629575452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X0700138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0169409X0700138X"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2007.06.011","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}